[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse FGF9

Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00167 Fibroblast growth factor
Function

Plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration. May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001649 osteoblast differentiation
GO:0001654 eye development
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002062 chondrocyte differentiation
GO:0006606 protein import into nucleus
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006913 nucleocytoplasmic transport
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007224 smoothened signaling pathway
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007530 sex determination
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0008584 male gonad development
GO:0008589 regulation of smoothened signaling pathway
GO:0008654 phospholipid biosynthetic process
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016055 Wnt signaling pathway
GO:0016202 regulation of striated muscle tissue development
GO:0017038 protein import
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0021762 substantia nigra development
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030238 male sex determination
GO:0030258 lipid modification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030326 embryonic limb morphogenesis
GO:0030901 midbrain development
GO:0030947 regulation of vascular endothelial growth factor receptor signaling pathway
GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway
GO:0032924 activin receptor signaling pathway
GO:0032925 regulation of activin receptor signaling pathway
GO:0032927 positive regulation of activin receptor signaling pathway
GO:0033002 muscle cell proliferation
GO:0034504 protein localization to nucleus
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035265 organ growth
GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process
GO:0040034 regulation of development, heterochronic
GO:0042471 ear morphogenesis
GO:0042472 inner ear morphogenesis
GO:0043410 positive regulation of MAPK cascade
GO:0043583 ear development
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0044744 protein targeting to nucleus
GO:0045017 glycerolipid biosynthetic process
GO:0045137 development of primary sexual characteristics
GO:0045844 positive regulation of striated muscle tissue development
GO:0045880 positive regulation of smoothened signaling pathway
GO:0045927 positive regulation of growth
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046546 development of primary male sexual characteristics
GO:0046620 regulation of organ growth
GO:0046622 positive regulation of organ growth
GO:0046661 male sex differentiation
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048505 regulation of timing of cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0048738 cardiac muscle tissue development
GO:0048839 inner ear development
GO:0048857 neural nucleus development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051216 cartilage development
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055023 positive regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0055123 digestive system development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060045 positive regulation of cardiac muscle cell proliferation
GO:0060070 canonical Wnt signaling pathway
GO:0060173 limb development
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060421 positive regulation of heart growth
GO:0060484 lung-associated mesenchyme development
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0071774 response to fibroblast growth factor
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090596 sensory organ morphogenesis
GO:0198738 cell-cell signaling by wnt
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1902593 single-organism nuclear import
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005104 fibroblast growth factor receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008083 growth factor activity
GO:0008201 heparin binding
GO:0016303 1-phosphatidylinositol-3-kinase activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052742 phosphatidylinositol kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
GO:0070851 growth factor receptor binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-2033519: Activated point mutants of FGFR2
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-5654687: Downstream signaling of activated FGFR1
R-HSA-5654696: Downstream signaling of activated FGFR2
R-HSA-5654708: Downstream signaling of activated FGFR3
R-HSA-5654716: Downstream signaling of activated FGFR4
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-190242: FGFR1 ligand binding and activation
R-HSA-1839124: FGFR1 mutant receptor activation
R-HSA-190373: FGFR1c ligand binding and activation
R-HSA-190241: FGFR2 ligand binding and activation
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-190375: FGFR2c ligand binding and activation
R-HSA-190239: FGFR3 ligand binding and activation
R-HSA-2033514: FGFR3 mutant receptor activation
R-HSA-190371: FGFR3b ligand binding and activation
R-HSA-190372: FGFR3c ligand binding and activation
R-HSA-190322: FGFR4 ligand binding and activation
R-HSA-5654693: FRS-mediated FGFR1 signaling
R-HSA-5654700: FRS-mediated FGFR2 signaling
R-HSA-5654706: FRS-mediated FGFR3 signaling
R-HSA-5654712: FRS-mediated FGFR4 signaling
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5654726: Negative regulation of FGFR1 signaling
R-HSA-5654727: Negative regulation of FGFR2 signaling
R-HSA-5654732: Negative regulation of FGFR3 signaling
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-5654689: PI-3K cascade
R-HSA-5654695: PI-3K cascade
R-HSA-5654710: PI-3K cascade
R-HSA-5654720: PI-3K cascade
R-HSA-109704: PI3K Cascade
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-5654219: Phospholipase C-mediated cascade
R-HSA-5654221: Phospholipase C-mediated cascade; FGFR2
R-HSA-5654227: Phospholipase C-mediated cascade; FGFR3
R-HSA-5654228: Phospholipase C-mediated cascade; FGFR4
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-5654688: SHC-mediated cascade
R-HSA-5654699: SHC-mediated cascade
R-HSA-5654704: SHC-mediated cascade
R-HSA-5654719: SHC-mediated cascade
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654736: Signaling by FGFR1
R-HSA-5655302: Signaling by FGFR1 in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-5654741: Signaling by FGFR3
R-HSA-5655332: Signaling by FGFR3 in disease
R-HSA-8853338: Signaling by FGFR3 point mutants in cancer
R-HSA-5654743: Signaling by FGFR4
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-1839122: Signaling by activated point mutants of FGFR1
R-HSA-1839130: Signaling by activated point mutants of FGFR3
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FGF9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FGF9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29656749lung adenocarcinomaInhibit immunity (T cell function)We have developed a mouse model of lung cancer that is initiated through an inducible overexpression of fibroblast growth factor 9 (FGF9) in type-2 pneumocytes.
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FGF9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FGF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3620.136
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5860.318
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2020.642
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6370.226
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.4070.2
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3310.816
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2460.808
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5050.743
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0550.524
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2880.559
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8020.25
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1010.71
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FGF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FGF9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FGF9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FGF9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FGF9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FGF9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FGF9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFGF9
Namefibroblast growth factor 9
Aliases glia-activating factor; fibroblast growth factor 9 (glia-activating factor); FGF-9; GAF; HBFG-9; HBGF-9; SYN ......
Chromosomal Location13q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FGF9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.